Anti-PEDF antibody

Anti-PEDF antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit monoclonal to PEDF

WB

Human SerpinF1 / PEDF

OI6 antibody; AI195227 antibody; EPC-1 antibody; EPC-1 antibody; PEDF antibody; Pedf antibody; Pedfl antibody; PIG35 antibody; RP23-384C18.1 antibody; Sdf3 antibody; SERPINF1 antibody; Serpinf1 antibody; OI12 antibody; PEDF antibody; EPC-1 antibody; PIG35 antibody; Pedf antibody; Sdf3 antibody; EPC-1 antibody; Pedfl antibody; AI195227 antibody

Rabbit IgG

This antibody was obtained from a rabbit immunized with purified, recombinant Human SerpinF1 / PEDF (rh SerpinF1 / PEDF; NP_002606.3; Met1-Pro418).

Monoclonal

0.2 μm filtered solution in PBS with 5% treha

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

Pigment epithelium-derived factor, also known as PEDF, Serpin F1, and SERPINF1, is a multiple functional protein which has both anti-angiogenic activity and neurotrophic activity at the same time. PEDF is a secreted glycoprotein that belongs to the noninhibitory serpin. It has an alpha/beta core serine-protease inhibitor domain, three major beta-sheets, and ten alpha-helices. PEDF does not inhibit either serine or cysteine proteinases. PEDF exerts diverse physiological activities including anti-angiogenesis, anti-vasopermeability, anti-tumor, and neurotrophic activities. PEDF acts via multiple high affinity ligands and cell receptors. It has been described as a natural angiogenesis inhibitor with neurotrophic and immune-modulation properties. PEDF induces macrophages apoptosis and necrosis through the activation of peroxisome proliferator-activated receptor-gamma by which PEDF could modulate inflammatory reactions in septic shock. It balances angiogenesis in the eye and blocks tumor progression.

• Ren, JG. et al., 2005, Med Hypotheses. 64 (1): 74-8.
• Filleur, S. et al., 2009. J Cell Biochem. 106 (5): 769-75.
• Kawaguchi, T. et al., 2010, Curr Mol Med. 10 (3): 302-11.
• Yamagishi, SI. et al., 2010, Curr Mol Med. 10 (3): 284-91.
• Nakamura, T. et al., 2010, Curr Mol Med. 10 (3): 312-6.